Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Health Canada.
Up to now, the product has been marketed in China, the United States, Israel, Australia and Singapore. The approval of the product in Canada will bring a positive impact on future oversea business growth.
SinoT is a specialty pharma with focus on the research & development, commercialization and sale of complex generics and 505(b2) products. We dedicated to developing high quality medicines that meet with international standards. We’ll do more than our best to benefit the patients in the future.
Posaconazole is a member of the group of triazole antifungals，which is used to prevent certain kinds of fungal or yeast infections. With the increasing number of high-risk patients such as cancer chemotherapy, transplantation, HIV/AIDS infection, and diabetes, the overall incidence of invasive fungal infections (IFIs) continues to rise. Different from other drugs used to treat IFIs, posaconazole can be used to prevent IFIs , so it has a broad market prospect.